Hisamitsu Pharmaceutical Co., Inc.
Other OTCTotal Valuation
Hisamitsu Pharmaceutical Co., Inc. carries a market capitalization of 2.04B, placing it among publicly traded companies globally. Its enterprise value stands at 149.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.04B |
| Enterprise Value | 149.86B |
Share Statistics
Hisamitsu Pharmaceutical Co., Inc. currently has 73.34M shares outstanding.
| Shares Outstanding | 73.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hisamitsu Pharmaceutical Co., Inc. trades at a trailing price-to-earnings ratio of 18.37. The price-to-sales ratio is 1.79, and the price-to-book ratio stands at 1.05.
| PE Ratio | 18.37 |
| PS Ratio | 1.79 |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hisamitsu Pharmaceutical Co., Inc. trades at an EV/EBITDA multiple of 10.88 and an EV/FCF ratio of 7,558.99. The EV/Sales ratio of 1.00 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.88 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.00 |
| EV / EBITDA | 10.88 |
| EV / EBIT | 10.88 |
| EV / FCF | 7,558.99 |
Financial Position
Hisamitsu Pharmaceutical Co., Inc. maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.40, indicating conservative leverage, while an interest coverage ratio of 510.26 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.53 |
| Quick Ratio | 2.09 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 0.08 |
| Interest Coverage | 510.26 |
Financial Efficiency
Hisamitsu Pharmaceutical Co., Inc. posts a return on equity of 5.79 and a return on invested capital of 3.61.
| Return on Equity (ROE) | 5.79 |
| Return on Assets (ROA) | 4.22 |
| Return on Invested Capital (ROIC) | 3.61 |
| Return on Capital Employed (ROCE) | 5.52 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.01 |
Taxes
Over the trailing twelve months, Hisamitsu Pharmaceutical Co., Inc. has paid 5.49B in income taxes, reflecting an effective tax rate of 26.57.
| Income Tax | 5.49B |
| Effective Tax Rate | 26.57 |
Stock Price Statistics
Hisamitsu Pharmaceutical Co., Inc.'s stock has declined approximately -10.21672% over the past 52 weeks. The 50-day moving average sits at 29.00, while the 200-day moving average is 29.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -10.21672% |
| 50-Day Moving Average | 29.00 |
| 200-Day Moving Average | 29.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hisamitsu Pharmaceutical Co., Inc. generated 150.19B in revenue and converted that into 14.65B in net income, yielding earnings per share of 202.10. EBITDA reached 13.78B, while operating income came in at 13.78B.
| Revenue | 150.19B |
| Gross Profit | 84.73B |
| Operating Income | 13.78B |
| Pretax Income | 20.65B |
| Net Income | 14.65B |
| EBITDA | 13.78B |
| EBIT | 13.78B |
| Earnings Per Share (EPS) | 202.10 |
Balance Sheet
Hisamitsu Pharmaceutical Co., Inc. holds 122.74B in cash and equivalents against 1.12B in total debt, resulting in a net debt position of -112.45B. Total book value stands at 256.98B, with working capital of 148.44B providing operational flexibility.
| Cash & Cash Equivalents | 122.74B |
| Total Debt | 1.12B |
| Net Debt | -112.45B |
| Equity (Book Value) | 256.98B |
| Book Value Per Share | 3,429.11 |
| Working Capital | 148.44B |
Margins
Hisamitsu Pharmaceutical Co., Inc. operates with a gross margin of 56.42, reflecting its pricing power and cost economics. The operating margin of 9.17 and net profit margin of 9.75 provide insight into operational efficiency.
| Gross Margin | 56.42 |
| Operating Margin | 9.17 |
| Pretax Margin | 13.75 |
| Profit Margin | 9.75 |
| EBITDA Margin | 9.17 |
Scores
Hisamitsu Pharmaceutical Co., Inc. posts an Altman Z-Score of 4.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.26 |